For any biotech or pharma company outsourcing manufacturing, the difference between a single clean inspection and a flawless record across every facility worldwide can be the deciding factor in whether to hand over a program. WuXi AppTec is making the case that consistency across its entire global network is not just a goal but a measurable outcome, citing 2,008 audits completed without a single critical finding over two and a half years.
SAN DIEGO, CA, UNITED STATES, October 11, 2026 /EINPresswire.com/ — Key Takeaways
WuXi AppTec operates a single “One Global Quality System” across every site it runs, rather than permitting each location to establish its own independent standards.
Across the three most recent reporting periods, WuXi AppTec completed 802 quality audits in 2024, 741 in 2025, and 465 in the first half of 2026, all concluding with no critical findings.
Case Study: WuXi AppTec’s Couvet, Switzerland site assumed a client’s Phase 3 manufacturing operation within five months, and the same facility subsequently passed inspections by three distinct regulators—Swissmedic, the FDA, and Brazil’s ANVISA—without any halt in production.
Virtually any CDMO can produce a single favorable audit report upon request. But the more telling question is whether that same standard of quality holds true across every facility the company operates—and that is where answers often become inconsistent. From 2024 through the first half of 2026, WuXi AppTec underwent 2,008 quality audits and inspections conducted by global customers, regulatory authorities, and independent third parties, and not one resulted in a critical finding. For a biotech or pharma company preparing to transfer a program, that track record determines whether they can trust the receiving site without conducting exhaustive verification on their own.
WuXi AppTec Addresses Inconsistency Through One Global Quality System
WuXi AppTec tackles variation throughout its worldwide network by employing its “One Global Quality System,” which harmonizes quality standards, procedures, and training across all locations. Global computerized systems ensure consistent documentation and oversight, while standardized GMP procedures establish uniform expectations for day-to-day operations. At its Couvet, Switzerland, manufacturing site, for instance, the company implemented the same global procedures, computerized systems, and training used throughout the network. Quality assurance leaders from other sites collaborated with local teams to align existing processes with the global framework.
This strategy directly confronts the practical difficulties of international collaboration. Growth driven by new construction, acquisitions, and joint ventures can produce facilities with differing operational histories, equipment, documentation practices, and interpretations of GMP requirements. Without deliberate alignment, those discrepancies can create gaps in how teams document work, manage changes, and demonstrate that employees are qualified for their responsibilities.
Harmonized procedures, shared quality management systems, and common training requirements help convert global standards into consistent daily practice. They provide teams with a unified foundation for recording activities, reviewing decisions, and identifying issues as programs move between locations. The ongoing challenge lies in maintaining that discipline as the network expands, ensuring each site upholds the same expectations.
WuXi AppTec Helps Customers Navigate Transitions Between Sites
According to Dirk Tormans, WuXi AppTec’s Head of QA, a qualification audit conducted at an API facility may enable customers to reduce the time spent reviewing the same quality elements at a downstream drug-product site.
That advantage becomes critical when a program advances to a new development stage, demands additional capacity, or extends production into another region. Customers must evaluate whether the receiving site is capable of performing the work while maintaining the program’s quality requirements. Prior familiarity with the broader quality framework allows them to focus on the questions specific to that transition, including equipment suitability, process transfer, and analytical readiness.
WuXi AppTec’s Site Examples Demonstrate Quality in Practice
WuXi AppTec’s Couvet, Switzerland, facility serves as an example of how an established manufacturing operation can support a time-sensitive transition. In one program, the site assumed production of a Phase 3 drug previously manufactured at the client’s own facility. Teams worked concurrently on equipment compatibility assessments, analytical method validation, and procurement of raw and packaging materials. The process transfer and scale-up were completed within five months, enabling the client to submit its New Drug Application on schedule.
Separately, Couvet’s integration into the global quality framework provides a demonstration of consistency under regulatory oversight. Inspections conducted by Swissmedic, the U.S. FDA, and Brazil’s ANVISA proceeded without any interruption to production following the site’s alignment with the global system.
The company is also embedding quality into new facilities before operations begin. At Middletown, Delaware, and Singapore, WuXi AppTec applies an approach that positions leaders early and establishes quality systems ahead of production. These examples address two practical tests of a global network: preparing work for an existing facility and preparing new capacity to function within the same quality framework from day one.
WuXi AppTec’s Quality System Lets Programs Move Fast Without Losing Trust
A quality system demonstrates its true value when speed becomes essential.
WuXi AppTec’s Couvet, Switzerland site illustrates this point well. The facility took over Phase 3 manufacturing that a client had previously managed at its own location, integrating an unfamiliar process into an already-audited quality framework rather than constructing oversight from the ground up. Multiple teams completed the equipment compatibility checks, analytical method validation, and materials procurement required for the transition within five months, and the client submitted its NDA on time.
That transition also withstood external examination. Switzerland’s Swissmedic, the U.S. FDA, and Brazil’s ANVISA all inspected the site afterward, and in every instance, production continued throughout the inspection rather than pausing for it.
WuXi AppTec is applying the same principle to facilities that have not yet opened. At Middletown, Delaware, and at its Singapore site, quality leadership and systems are already established before the first batch is run, enabling the new facility to begin within the global standard instead of being integrated into it later.
This kind of transfer only succeeds if the receiving site’s quality system is already trusted. A client should not have to start verification from zero once the clock is ticking.
The same reasoning underpins WuXi AppTec’s oral peptide work, where the company has supported more than 70 preclinical and over 10 clinical-stage programs without each one requiring its own separate quality build-out. For a company selecting a manufacturing partner, global quality must mean a system that allows a program to move between teams, sites, and stages without sacrificing the standard it started with.
That is the benchmark a biotech or pharma company evaluates when assessing a partner: a quality system backed by an actual track record.
Why it matters: As drugmakers increasingly rely on CDMOs for complex and time-sensitive manufacturing, the ability to transfer programs across global sites without re-verifying quality from scratch becomes a competitive advantage. WuXi AppTec’s audit record suggests that a unified quality framework can support both regulatory compliance and operational speed, setting a benchmark for what sponsors should expect from their partners.
WuXi AppTec
WuXi AppTec
wuxiconcierge@wuxiapptec.com
